ONCONETIX INC (ONCO)
US09610B1089 - Common Stock
ONCONETIX INC
NASDAQ:ONCO (11/27/2024, 8:58:00 PM)
After market: 0.8399 +0.18 (+26.87%)0.662
+0.03 (+5.08%)
Company Profile
Onconetix Inc is a US-based company operating in Biotechnology industry. The company is headquartered in Cincinnati, Ohio and currently employs 12 full-time employees. The company went IPO on 2022-02-18. Onconetix, Inc. is a commercial stage biotechnology company. The company is focused on the research, development and commercialization of proprietary therapeutics, diagnostics and services for clinicians and patients for oncology. The company has Entadfi, a Food and Drug Administration approved, oral therapeutic for the treatment of benign prostatic hyperplasia (BPH), a disorder of the prostate, and Proclarix, an advanced proprietary diagnostic system for screening and diagnosis for men with indeterminate Prostate Specific Antigen (PSA) assessments in prostate cancer oncology. Entadfi is a once-daily, oral treatment for BPH that combines finasteride, a 5α-reductase inhibitor, and tadalafil, a phosphodiesterase 5 (PDE5) inhibitor. Proclarix is a next generation protein-based blood test that can be done with the same sample as a patient’s regular PSA test. Proteomedix is seeking to develop diagnostic, prognostic, and predictive tools to enable cancer management at all stages of disease progression.
Company Info
ONCONETIX INC
201 E. Fifth Street, Suite 1900
Cincinnati OHIO
P: 15136204101
Employees: 12
Website: https://onconetix.gcs-web.com/
ONCO News
10 hours ago - ChartmillCurious about the stocks that are showing activity after the closing bell on Thursday?Which stocks are moving after the closing bell on Thursday?
2 months ago - Onconetix, Inc.Correction: Onconetix Announces Financing Through a $2.0 Million Private Placement of Series C Preferred Stock and Warrants, Establishes a $25 Million Equity Line of Credit2 months ago - Onconetix, Inc.Correction: Onconetix Announces Financing Through a $2.0 Million Private Placement of Series C Preferred Stock and Warrants, Establishes a $25 Million Equity Line of CreditCINCINATTI, OH., Oct. 03, 2024 (GLOBE NEWSWIRE) -- In a release issued under the same headline earlier today by Onconetix, Inc. (Nasdaq: ONCO), please...
2 months ago - Onconetix, Inc.Onconetix Announces Financing Through a $2.0 Million Private Placement of Series C Preferred Stock and Warrants, Establishes a $25 Million Equity Line of Credit2 months ago - Onconetix, Inc.Onconetix Announces Financing Through a $2.0 Million Private Placement of Series C Preferred Stock and Warrants, Establishes a $25 Million Equity Line of CreditCINCINATTI, Oh., Oct. 03, 2024 (GLOBE NEWSWIRE) -- Onconetix, Inc. (Nasdaq: ONCO) (“Onconetix” or “the Company”) (formerly Blue Water Biotech, Inc....
2 months ago - Onconetix, Inc.Onconetix, Inc. Announces 1-for-40 Reverse Stock Split and Results of the Annual Meeting of StockholdersONCO Twits
Here you can normally see the latest stock twits on ONCO, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits:
